Population Pharmacokinetics of Lassila Tazobactam in Patients After Aortic Dissection

NCT05349305 | Unknown FDA Drug

• 1 other identifier: byssc1985
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

The individualized drug use research on optimizing piperacillin tazobactam for CRRT of hospital-acquired pulmonary infection after cardiopulmonary bypass is still in the initial stage at home and abroad, lacking systematic research data. With the help of the population pharmacokinetic model, it can help clinicians to formulate individualized drug administration plans for such patients and provide methodological and data support for precise treatment. The rational use of piperacillin tazobactam will play an important role in reducing the use of carbapenems and curbing the occurrence of drug resistance.

Conditions

Aortic Dissection; Lung Infection

Keywords

Piperacillin tazobactam; CRRT

Outcome Measures

Primary Outcomes (1)

• blood concentration

  Blood concentration of piperacillin and tazobactam in whole period after administration

  Up to 8 hours after administration

Interventions

continuous renal replacement therapy DRUG

continuous renal replacement therapy

Also known as: non

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Adult patients with pulmonary infection after aortic dissection treated with CRRT and piperacillin tazobactam

You may qualify if:

• Cardiopulmonary bypass during aortic dissection， Lung infection， Continuous renal replacement therapy

You may not qualify if:

• Intracranial infection, Urinary tract infection

Sponsors & Collaborators

• The Second Hospital of Shandong University: lead

MeSH Terms

Conditions

Aortic Dissection

Interventions

Continuous Renal Replacement Therapy

Condition Hierarchy (Ancestors)

Dissection, Blood Vessel; Aneurysm; Vascular Diseases; Cardiovascular Diseases; Acute Aortic Syndrome; Aortic Diseases

Intervention Hierarchy (Ancestors)

Renal Replacement Therapy; Therapeutics; Extracorporeal Circulation; Surgical Procedures, Operative

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 19, 2022
• First Posted: April 27, 2022
• Study Start: April 30, 2022
• Primary Completion: December 31, 2023
• Study Completion: July 30, 2024
• Last Updated: April 27, 2022

Record last verified: 2022-04